An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse effects and withdrawal, while emphasizing emerging nonsteroidal therapies as promising safer alternatives for personalized care.

An expert discusses the shift from reactive to proactive treatment of atopic dermatitis (AD), emphasizing personalized care and the growing role of advanced nonsteroidal topicals—such as PDE4 and JAK inhibitors—alongside updated guidelines aimed at improving clinician awareness and patient outcomes.

An expert discusses proactive management strategies for atopic dermatitis (AD), emphasizing daily gentle skin care, proper use of topical treatments, avoidance of outdated therapies such as routine antihistamines or steroids, and a shift toward personalized, flare-preventive care using newer therapeutic options.

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body surface area (BSA) estimation, and the Pruritus Numerical Rating Scale (NRS) to guide personalized treatment and improve symptom tracking in routine clinical care.

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar conditions, and the critical role of education and skin care in effective management, particularly in primary care settings.

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of collaboration between dermatology and primary care providers to improve patient outcomes.

Your daily dose of the clinical news you may have missed.

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Jonathan Bonnet, MD, MPH, discusses common side effects of GLP-1 medications for obesity and how nutritional and behavioral strategies can help mitigate them.

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.

Your daily dose of the clinical news you may have missed.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.

Your daily dose of the clinical news you may have missed.

Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.

Shagun Bindlish, MD, board member of the ADA, discusses how societal weight-related stigma contributes to mental health challenges faced by women with obesity.

Your daily dose of the clinical news you may have missed.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say.

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.

The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.